



Obesity Medications in Clinical Trials

What's coming next · Data as of September 2026 · All investigational, not FDA approved

	Retatrutide	Bimagrumab	Cagrilintide	MariTide	Survodutide	Eloralintide	Amycretin
Company	Eli Lilly	Eli Lilly	Novo Nordisk	Amgen	Boehringer Ingelheim / Zealand	Eli Lilly	Novo Nordisk
Mechanism	GIP + GLP-1 + glucagon agonist ("triple G") · weekly	Blocks activin type II receptors, preserving and building muscle · IV	Amylin agonist · weekly + semaglutide = CagriSema	GLP-1 agonist + GIP antagonist · monthly	Glucagon + GLP-1 agonist · weekly	Amylin receptor agonist · weekly	One molecule acting on GLP-1 + amylin receptors
Trial	TRIUMPH Phase 3	BELIEVE Phase 2b	REDEFINE Phase 3	MARITIME Phase 2 → 3	SYNCHRO-NIZE-1 Phase 3	ENLIGHTEN Phase 3 (began 2026)	Early trial Phase 1b/2a
Weight loss	-28.3% at 80 wk (12 mg) -30.3% at 104 wk (extension)	-20% with semaglutide -10% alone Fat mass: -42% combo, -25% alone	-22.7% as CagriSema -11.8% alone vs tirzepatide: 23% vs 25.5%	-20% at 52 wk (no diabetes)	-16.6% at 76 wk vs -3.2% placebo	-20% at 48 wk (9 mg, Phase 2)	-24.3% at 36 wk vs -1.1% placebo
Most common side effects	Nausea 42% Diarrhea 32% Dysesthesia 12.5%	Muscle spasms, diarrhea % not reported	CagriSema: Nausea 55% Constipation 31%	Nausea, vomiting % not reported	Nausea 65% Vomiting 45%	Nausea 64% Fatigue 46% (6 mg)	Nausea, vomiting % not reported
Stopped due to side effects	11.3%	14–21% alone, 5–13% combo	CagriSema 5.9% Alone 2.6% (1.0% for nausea)	~11%	24.8%	not reported	not reported
Notes	—	Muscle mass: +2.5% alone -3% combo -7% semaglutide alone	—	No weight-loss plateau seen	—	—	Small, early study
Expected	2027–2028	Several years	CagriSema: late 2026 Alone: several years	2028	2027–2028	TBD	TBD

Much of this data is company-reported and not yet fully peer-reviewed. Trials differ in length and population, so numbers aren't directly comparable. Dates are estimates.